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Abstract
Background: Patients with Ph-negative myeloproliferative neoplasms (MPN), such as polycythemia vera (PV), essential
thrombocythemia (ET), and primary myelofibrosis (PMF), are at increased risk for thrombosis/thromboembolism and
major bleeding. Due to the morbidity and mortality of these events, antiplatelet and/or anticoagulant agents are
commonly employed as primary and/or secondary prophylaxis. On the other hand, disease-related bleeding
complications (i.e., from esophageal varices) are common in patients with MPN. This analysis was performed
to define the frequency of such events, identify risk factors, and assess antiplatelet/anticoagulant therapy in a
cohort of patients with MPN.
Methods: The MPN registry of the Study Alliance Leukemia is a non-interventional prospective study including adult
patients with an MPN according to WHO criteria (2008). For statistical analysis, descriptive methods and tests for
significant differences as well as contingency tables were used to identify the odds of potential risk factors for vascular
events.
Results: MPN subgroups significantly differed in sex distribution, age at diagnosis, blood counts, LDH levels, JAK2V617F
positivity, and spleen size (length). While most thromboembolic events occurred around the time of MPN diagnosis,
one third of these events occurred after that date. Splanchnic vein thrombosis was most frequent in post-PV-MF and
MPN-U patients. The chance of developing a thromboembolic event was significantly elevated if patients suffered from
post-PV-MF (OR 3.43; 95 % CI = 1.39–8.48) and splenomegaly (OR 1.76; 95 % CI = 1.15–2.71). Significant odds for major
bleeding were previous thromboembolic events (OR = 2.71; 95 % CI = 1.36–5.40), splenomegaly (OR = 2.22; 95 % CI
1.01–4.89), and the administration of heparin (OR = 5.64; 95 % CI = 1.84–17.34). Major bleeding episodes were
significantly less frequent in ET patients compared to other MPN subgroups.
Conclusions: Together, this report on an unselected “real-world” cohort of German MPN patients reveals important
data on the prevalence, diagnosis, and treatment of thromboembolic and major bleeding complications of MPN.
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Background
Philadelphia-chromosome (Ph-neg) negative myelopro-
liferative neoplasms (MPN) are a heterogeneous group
of rare hematopoietic stem cell clonal diseases. Accord-
ing to the WHO 2008 classification, Ph-neg MPN in-
clude classical MPN, such as essential thrombocythemia
(ET), polycythemia vera (PV), and primary myelofibrosis
(PMF), as well as less common entities such as chronic
neutrophilic leukemia (CNL), hypereosinophilic syn-
drome (HES), systemic mastocytosis (SM), and unclassi-
fiable MPN (MPN-U) [1]. Various recurrent molecular
alterations have been described in classical MPN, such
as JAK2 V617F [2], MPL W515L/K [3], or MPL S505
mutations and deletion or insertions in the calreticulin
gene. In addition, further mutations in other genes, such
as CBL, CHEK2, DNMT3A, ASXL1, EZH2, IDH1/2,
SF3B1, SH2B3 (LNK), SETBP1, SRSF2, and TET2, have
been found in MPN [4–7].
These genetic factors at least in part play a causal role
in the disease pathogenesis of MPN and have greatly fa-
cilitated the diagnostic work-up [8].
MPN are known to be associated with an increased
risk of thrombotic and thromboembolic events com-
pared to the general population, and these events con-
tribute considerably to morbidity and mortality of MPN
[9–14]. On the other hand, MPN patients are also at a
higher risk for bleeding complications due to antiplatelet
and anticoagulant therapy necessary to prevent major
thromboembolic complications in high-risk patients. An-
other important risk factor for bleeding complications is
the presence of esophageal or gastric varices due to por-
tal vein hypertension and/or an acquired von Willebrand
syndrome (AVWS) due to excessive thrombocytosis
[15–18].
During the last decade, novel insights into the patho-
genesis and the risk factors of thromboembolic events in
MPN have been gained. Apart from known thrombosis-
associated risk factors such as a previous thrombotic
event or age of the patient, typical MPN-associated risk
factors have also been described [19]. Endothelial activa-
tion, polyglobulia (PV), and leukocyte activation [20–22]
are among the most relevant risk factors, while divergent
results were reported regarding high platelet counts and
thrombosis [9, 23]. Notably, JAK2 positivity is also a
strong risk factor for vascular events when compared to
JAK2 Ph-negative MPN. In contrast, MPL and calreticu-
lin mutations are not associated with an increased risk
of thrombosis [8, 9, 24, 25].
Regarding bleeding risk, disease-related as well as
therapy-associated factors have to be considered, includ-
ing anticoagulation with vitamin K antagonists (VKA),
novel anticoagulatory drugs (NOAC), and antiplatelet
therapy [26] but also AVWS [27] and storage pool de-
fects with a downregulation of glycoprotein (GP)Ib and
GPIIb/IIIa [28]. The role of an imbalance of distinct
platelet surface receptors is still debated, since platelet
surface receptor expression also differs significantly in
“healthy” subjects [29]. However, there is evidence for a
direct effect of JAK2 V617F, which has been docu-
mented to influence platelet activation in ET via a
complex mechanism of the PI3K/Rap1 pathway leading
to impaired thrombopoietin-mediated integrin IIb 3
activation [30]. Furthermore, hypersplenism and
thrombocytopenia may also enhance the risk of bleed-
ing, especially in MF patients.
This analysis of data from the MPN registry of the
German Study Alliance Leukemia (SAL) was performed
to describe, in a “real-world” setting of German MPN
patient care, the incidence of thrombotic and thrombo-
embolic as well as major bleeding events before, at the
time of diagnosis and during clinical follow-up of Ph-
negative MPN patients with a particular focus on the
underlying diagnosis, treatment modality, and patient-
related factors potentially affecting vascular events in
MPN. The ultimate goal of this study was to elucidate
vascular and bleeding complications in a representative
group of patients with Ph-negative MPN and to identify
potential risk factors for the development of these
events.
Results
Patients’ general characteristics are shown in Table 1.
Among the MPN subtypes, significant differences were
observed for gender, JAK2 V617F status, spleen size, and
relevant laboratory parameters. Figure 1 shows the dis-
tribution of the MPN subtypes included in this MPN
registry. Ninety-four percent of all cases were so-called
classical MPN, such as PV, ET, and primary and second-
ary myelofibrosis, while 4 % were MPN-U cases.
Of all patients, 33.6 % suffered from a vascular event.
The most frequent events were deep vein thrombosis
(31.5 %), acute coronary syndrome (27.7 %), stroke
(19.3 %), and splanchnic vein thrombosis (15.2 %). For
splanchnic vein thrombosis, a significant difference be-
tween the MPN subtypes was detected (p = 0.0083)
(Table 2), as it was most frequent in MPN-U (60 %),
followed by post-PV MF (30.8 %).
Major bleeding events were reported in 8.2 % of all pa-
tients, with upper gastrointestinal bleedings being most
common (55.6 % of all bleeding occurrences), and other
bleeding causes being significantly less frequent. As
shown in Table 2, we detected significant differences in
the proportion of major bleeding between the different
MPN subtypes.
Figure 2 shows the number of thrombotic/thrombo-
embolic and bleeding events over time in relation to the
date of diagnosis (time point “zero”). For vascular occlu-
sions, the distribution of events was similar before and
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Table 1 General characteristics of all patients with MPN (n = 455)
All patients PV ET PMF Post-PV-MF Post-ET-MF MPN-U p value
Patients; n (% of total) 454 142 (31.3) 140 (30.8) 113 (24.9) 22 (4.8) 19 (4.2) 18 (4.0)









































































































*Wilcoxon-Mann-Whitney test; #Chi-square test















after MPN diagnosis (Fig. 2 a). In contrast, hemorrhages
were only rarely detected before diagnosis, as only two
out of 36 events occurred prior to diagnosis, whereas all
other bleeding events occurred after MPN had been di-
agnosed (Fig. 2b). Bleeding may be supported by anti-
platelet and anticoagulant therapy; thus, we next
evaluated their association with bleeding episodes.
In the overall cohort, antiplatelet and anticoagulant
therapy was frequently applied. Most patients were ex-
posed to acetylsalicylic acid (ASS) (57.4 % of all patients)
and oral VKA (almost 10 %). Of note, eight patients
(1.8 %) received the NOAC rivaroxaban.
With regard to the MPN-specific therapy, watchful
waiting strategies were most frequently applied (51.7 %),
followed by the use of hydroxyurea (49.2 %) as cytore-
ductive therapy (Table 3). Based on the long clinical
course, patients received different substances and/or
therapy regimes during their follow-up. In 87 patients
(19.9 %), the JAK1/2 inhibitor ruxolitinib was adminis-
tered, most frequently in MF patients (Table 3).
As expected, the type of MPN therapy differed signifi-
cantly among the MPN subtypes (Table 3), except for
interferon alpha (n.s. most likely due to small numbers


















Fig. 1 Distribution of the MPN subtypes in the registry (n = 466). Classical MPN, PV, ET, and PMF represent 85 % of all subtypes, followed by post-
PV and post-ET myelofibrosis and MPN-U. Documentation of CNL, HES/CEL, SM, and MPN with a PDGFR-alpha, PDGFR-beta, or FGFR1-aberration
was infrequent (together 2.4 % of all subtypes)
Table 2 Thrombosis/thromboembolism and bleeding events in MPN
All Pts PV ET PMF Post-PV-MF Post-ET-MF MPN-U p value#







































































































































Pts patients, DVT deep vein thrombosis, ACS acute coronary syndrome, SVT splanchnic vein thrombosis, CNS central nervous system
#In Fisher’s exact test
aLife-time events
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Tables 4 and 5 show the odds for the development of
thrombotic/thromboembolic and major bleeding events.
Significantly elevated odds ratios for the occurrence of
thromboembolism were found for a diagnosis of post-
PV-MF and splenomegaly, but not the other subtypes,
JAK2 V617F, leukocytosis, or thrombocytosis (Table 4).
Significantly elevated odds ratios for major bleeding
events were found for those patients with a history of a
thrombotic or thromboembolic event, splenomegaly, and
those with a therapy with heparin. The administration of
a P2Y12 antagonist or double platelet inhibition showed
a positive trend for the latter (Table 5). Neither throm-
bocytosis nor thrombocytopenia nor the use of ASS,
VKA, or NOAC was associated with a significant odds
ratio for major bleeding events. Intriguingly, in our co-
hort, the diagnosis of ET was associated with a signifi-
cantly reduced odds ratio for major bleeding events as
compared to the other MPN subgroups, with a trend to-
wards higher bleeding frequencies in post-PV-MF and
MPN-U patients. Furthermore, the diagnosis ET showed
a protective effect for thrombotic/thromboembolic
events (OR = 0.56; 95 % CI 0.36–0.89). A subgroup ana-
lysis of patients with PMF, post-PV-MF, or post-ET-MF
showed that in all of these subgroups, a low platelet
count might be a mild risk factor for major bleeding
events but this did not reach statistical significance (data
not shown). In a logistic regression model for the predic-
tion of bleeding events, the variables age, splenomegaly,
thrombotic/thromboembolic event in medical history,
administration of ASS, P2Y12 antagonist, heparin, VKA,
and rivaroxaban were stepwise selected to enter and re-
main in the model. Only the variable “thrombotic/
thromboembolic event in medical history” showed a sig-
nificant effect (p = 0.0032).
For a multivariate logistic regression model (including
age class, splenomegaly, Jak2 status, high leukocytes,
high platelets, cancer) to predict thrombosis/thrombo-
embolism in our cohort, only splenomegaly was detected
to have a significant effect on the prediction of throm-
bosis/thromboembolism (p = 0.0009 in maximum likeli-
hood test).
Discussion
Arterial and venous thrombosis/thromboembolism sig-
nificantly contributes to morbidity and mortality of
MPN patients [18, 31]. We here describe the frequency
and risk factors for thrombotic/thromboembolic and

































Fig. 2 Number of thrombotic/thromboembolic (a) and major bleeding events (b) in MPN over time in months. The 0 (zero) marks the
date of diagnosis. In a (thrombotic and thromboembolic events), there are several events before and after diagnosis which presents
almost like a normal distribution. While in b (bleedings events), there were only two cases of major bleedings described before date of
diagnosis—all other major bleedings occurred after that date
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classical MPN and MPN-U in Germany, using clinical
data from the SAL-MPN registry. In contrast to many
clinical trials, our “real-world” analyses include a largely
unselected group of MPN patients, ranging from newly
diagnosed patients to those with a long disease history
and covering different health care service settings (univer-
sity hospitals, non-university hospitals, and office-based
physicians) mirroring organization of hematological pa-
tient care in the German health care system.
Approximately 50 % of analyzed patients were male
which is in accordance with recently published data [32],
whereas the median age at first diagnosis was consider-
ably lower (57 years) in our study. This difference may
be caused by a selection bias (selected MPN centers
documentation vs population-wide cancer registry) and
the time period of inclusion (2012–2015 vs 1980–2009).
Alternatively, the difference may be due to an earlier
diagnosis in today’s patients.
About one third of the evaluated patients suffered
from arterial or venous thromboembolism. DVT was the
most common event followed by cardiac events, which
is in accordance with previous findings [31, 33]. Regard-
ing the subtype analysis, especially in PV and ET, the oc-
currence of thromboembolic complications was similar
to previous findings [31, 34]. Interestingly, only in
approximately one quarter of patients developing a
Table 3 Antiplatelet and anticoagulant therapy and anti-MPN therapy
All patients PV ET PMF Post-PV-MF Post-ET-MF MPN-U p value#
Antiplatelet drugs






















































































































































































VKA vitamin K antagonist, WatchWait watchful waiting, SCT stem cell transplantation
#In Fisher’s exact test
aDouble platelet inhibition in n = 20 patients (4.72 %)
bLife-time therapy
cn = 114 patients (26 %) solely had watchful waiting strategy
Table 4 Odds ratios for thromboembolism









High leukocytes (>25/nl) 1.1500 0.6593–2.0059
High platelets (>1000/nl) 0.7163 0.3738–1.3727
Splenomegaly (detected by palpation) 1.7623 1.1480–2.7052
Kaifie et al. Journal of Hematology & Oncology  (2016) 9:18 Page 6 of 11
thrombosis/thromboembolism subsequent events were
registered, suggesting a lower frequency than in the pub-
lished literature (33.6 % [26]) and, possibly, a more ef-
fective cytoreduction, anticoagulation, or antiplatelet
therapy after the initial event.
Atypical venous thrombosis occurs more frequently
in MPN patients, when compared to patients without
MPN [35, 36]. We also report splanchnic vein throm-
bosis (SVT) accounting for 15 % of all thrombo-
embolic events. However, in our series, the
proportion of SVT in PV and ET was lower (2–5 %
in all patients) than previously reported in the litera-
ture (10–13 %) [34], and PV patients had less SVT
events compared to other MPN subtypes, which also
reached statistical significance in our cohort. Others
support our observation that SVT is less common in
PV compared to ET [31], whereas other studies did
not find significant differences in the different MPN
subgroups. Differences among the studies, including
our own, may be caused by a reporting bias or the
small numbers of events per group (e.g., only three
events in the PV group).
Patients from our cohort were less likely to develop
a recurrent thrombosis, with only one fifth of patients
in our cohort suffering from two or more thrombo-
embolic events, and this proportion was clearly lower
than in other studies (about 30 %) [26]. This may be
due to a lower MPN-dependent and MPN-
independent risk of thrombosis/thromboembolism, as
evidenced by the younger age of the patients in our
cohort and/or the high fraction of patients that were
followed by watchful waiting.
Our univariate analyses revealed that only post-PV-MF
diagnosis and splenomegaly were significant risk factors
for the development of a thrombotic/thromboembolic
event. In contrast to reports from the literature, a high
white blood count (WBC) and JAK2V617F positivity
were no identifiable risk factors for such events in our
study [9, 16, 21, 24, 26].
Thrombotic/thromboembolic events are crucial factors
of morbidity and mortality in PV and ET [10, 14, 37].
The particular time point of the events is meaningful,
notably to detect vulnerable phases in the clinical
course. In our cohort, most patients’ thrombotic/
thromboembolic events peaked around the time of diag-
nosis, with an almost normal distribution around this
time point. This suggests that thrombotic/thrombo-
embolic events constitute a major indicator of an MPN
and often triggers MPN diagnosis. However, it also sug-
gests that some patients may have thrombotic/thrombo-
embolic events already long before the diagnosis of
MPN. This should be taken into account when strategies
of enhancing public awareness of MPN and prevention
of thrombotic/thromboembolic complications are con-
cerned. Furthermore, the distribution of events may be
an indicator for successful strategies in preventing recur-
rent thrombotic/thromboembolic events and suggest
that a rigorous work-up regarding a potential underlying
MPN should be initiated, particularly in patients with
SVT.
Table 5 Odds ratios for major bleeding events








Thrombotic/thromboembolic event in medical history 2.7083 1.3578–5.4021
Splenomegaly (detected by palpation) 2.2222 1.0095–4.8919
Low platelets (<100/nl) 1.3120 0.5504–3.1275
High platelets (>1000/nl) 1.1874 0.4401–3.2035
ASS 1.1216 0.5539–2.2712
P2Y12 antagonist 2.8292 0.9979–8.0213
Double platelet inhibition 3.0500 0.9589–9.7016
Oral vitamin K antagonist 1.9739 0.7695–5.0634
Rivaroxaban 1.6092 0.1923–13.4665
Heparin 5.6426 1.8360–17.3421
Significant results are in italics
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Strikingly, the distribution of major bleedings followed
a different pattern, without a peak around diagnosis but
rather with most events occurring after the diagnosis of
an MPN. This suggests that major bleeding occurs as a
consequence of an MPN itself (i.e., ET-associated
AVWS), portal hypertension with esophageal varices due
to MPN-associated SVT, or primary prophylactic MPN
therapy (e.g., ASS in PV) or anticoagulation in patients
with previous thrombosis [27–29].
In our cohort, the overall major bleeding rate was
8 % which is close to the rates described in other
studies [26, 38, 39]. However, while nearly 10 % of
PV patients had a major hemorrhage, which is signifi-
cantly higher than in the published literature [38],
major bleeding rated in our ET patients were slightly
below the published data [38]. The reduced frequency
of bleedings in ET patients could be due to a higher
proportion of patients receiving cytoreduction as well
as the restrictive use of antiplatelet therapy with re-
gard to an acquired von Willebrand Syndrome
(AVWS), similar to what has been described for the
ANAHYDRET trial [39]. Furthermore, the OR of 0.34
as a protective effect of bleeding events corroborates
a careful and optimized therapy of ET patients docu-
mented in the SAL-MPN registry. Though the ET
diagnosis also leads to a protective effect for throm-
botic/thromboembolic events, an insufficient treat-
ment with antiplatelet or anticoagulative substances
cannot be assumed.
Current clinical guidelines recommend the administra-
tion of ASS for all PV patients to prevent thrombotic/
thromboembolic events [31]. However, only about two
third of PV patients in our series received ASS. Contra-
indications such as gastric ulcers and esophageal varices
were detected in 16 patients. Other reasons for the lack
of ASS administration could be the administration of
anticoagulant therapy (e.g., VKA), as the combination of
VKA and antiplatelet therapy should be only used with
caution [31]. Our data further illustrate that so far, only
a minority of patients with MPN received NOAC. And
the risk of bleeding cannot currently be adequately
assessed. However, with the development of the dabiga-
tran antidote idarucizumab, there are new therapeutic
options in case of major bleeding occurring in
dagibatran-treated patients [40].
In the analysis of potential risk factors for major bleed-
ing events, a previous history of vascular events, spleno-
megaly, and the administration of heparin were
identified. Interestingly, neither ASS nor VKA were
identified as risk factors. This lacking association, espe-
cially for patients receiving VKA, may be due to an in-
tense surveillance of this cohort. P2Y12 antagonists as
well as double-agent antiplatelet therapy narrowly
missed the significance level, possibly due to small
sample size (27 and 20 patients). These findings, espe-
cially the elevated odds of developing a major bleeding
with heparin, need to be evaluated in future prospective
studies. Although bleeding events are not the main cause
for mortality in MPN patients [41], the prevention of
such incidents is crucial, especially in case of long-term
antiplatelet and anticoagulative treatment [42]. Clinical
recommendations frequently discuss this topic and de-
velop strategies to prevent bleeding caused by the anti-
thrombotic medication [12, 17, 18, 31, 38].
In the past years, survival of MPN patients, especially
for PV and ET subtypes has improved [13], yet the relative
5-year survival for MPN patients in Germany decreases
from 92.3 % at ages 14–49 years to 63 % at 70+ years of
age [43]. Reasons for the higher mortality rates in elderly
patients were, in particular, thrombotic/thromboembolic
events [10, 14, 44]. Our cohort showed a low proportion
of recurrent thrombosis but a high frequency of throm-
bosis after the date of diagnosis. Intriguingly, 10 PV pa-
tients and 6 ET patients from our cohort had a
thrombotic/thromboembolic event but did not receive
cytoreductive therapy. Besides cytoreductive therapy for
high-risk PV and ET, control of cardiovascular risk factors
(smoking, dyslipidemia, hypertension) is crucial and
should not be neglected [10, 18, 21, 37, 45, 46].
We would like to discuss our findings with regard to
the already existing European LeukemiaNet (ELN)
guidelines [47] and guidelines of the German and Aus-
trian Society of Hematology and Oncology (DGHO/
ÖGHO) and the Society of Thrombosis and Haemostasis
Research (GTH) [31]. According to ELN guidelines,
antiplatelet therapy with ASS in PV patients is recom-
mended for all patients unless there is a contraindica-
tion. ASS was not shown to increase the bleeding risk in
this patient cohort. For ET patients, ASS is recom-
mended in case of microvascular disturbances according
to ELN guidelines. In all patients “aspirin should be
withdrawn in the event of major bleeding, most fre-
quently GI, or in the rare cases of allergy or intolerance”
[47]. Our own results, presented in this study, confirm
the safety of aspirin in this patient cohort. But we sug-
gest to restrict the use of aspirin in patients without a
clear indication. Furthermore, the ELN consortium gave
a detailed recommendation on SVT management.
“Treatment of splanchnic vein thrombosis includes low
molecular weight heparin followed by [life-long] oral
anticoagulation […]” [47]. However, the ELN recommen-
dations did not contain further detailed recommenda-
tions on the management of other thrombotic/
thromboembolic.
In our study, the administration of vitamin K antago-
nists (VKA) did not result in an increased major
bleeding risk, which is in accordance to the findings of
the DGHO/ÖGHO/GTH recommendations paper [31].
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Conversely, our study suggests that the administration
of P2Y12 antagonists might be associated with major
bleeding events. However, further evaluations are
needed, in light of the DGHO/ÖGHO/GTH guidelines
currently recommending the administration of P2Y12
antagonists in case of ASS allergy or intolerance [31].
Interestingly, in the RESPONSE trial, which assessed
the JAK inhibitor ruxolitinib vs standard therapy for the
treatment of polycythemia vera, a significant reduction
of thromboembolic events was seen in the ruxolitinib
group [48]. Since ruxolitinib is known to reduce spleen
size, we investigated whether enlargement of the spleen
is a risk factor for thrombotic/thromboembolic events.
Indeed, our study showed that splenomegaly was a risk
factor for thrombotic/thromboembolic events in our co-
hort. Potentially, a reduction of the spleen size in MPN
patients may be an attractive future goal to reduce the
incidence of thromboembolic events.
Several limitations of our study should be acknowl-
edged. As mentioned above, patients’ data were obtained
from MPN centers in Germany and not from a country-
wide cancer registry, which may be an explanation for
the lower median age of first diagnosis. Therefore, we
cannot exclude a selection bias, since the centers that
participate in our registry have a special interest in MPN
pathogenesis and treatment, rendering generalization of
the results difficult. Additionally, no data regarding
length, intensity, and combination of any specific or gen-
eral treatments was gathered. Furthermore, our cohort
was very broad regarding the time of data collection.
Some patients entered the registry at the time of diagno-
sis and others after a long latency period. It is imagin-
able that, in particular for patients with longstanding
MPN history, thrombotic/thromboembolic, or bleeding
events may have been underreported if they occurred
before referral to the participating centers. The number
of patients and the low incidence of these diseases (1–3
per 100 000 inhabitants) is also a limiting factor of this
study and might affect our results.
On the other hand, the strength of our registry is the
inclusion of patient data from academic centers, com-
munity hospitals, or office-based environments, provid-
ing a representative picture of MPN-care in Germany.
Thus, the reported patients much more reflect the “real-
world” population without the plethora or restrictings
generated by stringent in-/exclusion criteria of patients
treated in controlled clinical trials.
Conclusions
In summary, thrombotic/thromboembolic and bleeding
events play an important role in the clinical course of
MPN patients. However, one third of all thrombotic/
thromboembolic events in our registry occurred after
diagnosis, although it is known that these events mainly
lead to morbidity and mortality in MPN patients, and
standard treatment of PV patients (i.e., with ASS) did
not always reflect current clinical guidelines. Thus, it will
be important to address these points in the future obser-
vation and interventional clinical trials. On the other
hand, ET patients showed a reduced occurrence of
bleeding complications which may be an indicator that
the risk factors for major hemorrhages in these patients
are well appreciated in the clinical practice nowadays
and that current therapy concepts appropriately address
these risk factors.
Methods
Patients and clinical data
The German SAL-MPN registry is a national prospective
observational study with several university hospitals,
community hospitals, and hematology/oncology prac-
tices participating in the documentation of patients with
MPN. Inclusion criteria were the following: a confirmed
MPN diagnosis according to the WHO classification
(2008) or IWG-MRT criteria, patient age of 18 years or
older, and written informed consent by the patient. The
MPN registry is approved by the Ethics Committee of
the Medical Faculty of RWTH Aachen University (EK
127/12) as well as each local Ethics Committees of the
participating centers. Patient recruitment started in
August 2012, the here presented contain clinical data
from 454 patients with PV, ET, PMF, post-PV-MF, post-
ET-MF, and MPN-U that were available for statistical
analyses until data lock in February 2015.
Clinical data include laboratory results, molecular gen-
etics, clinical signs and symptoms, and complications
such as vascular or major bleeding events (defined as
intracranial or retroperitoneal bleed or associated with a
decrease in hemoglobin ≥2 g/dl or requiring of blood
transfusions [38]) as well as concomitant medication
and MPN-specific therapy.
Statistical analysis
Clinical data was collected and analyzed using SAS
Software (SAS 9.3, SAS Institute Inc., Cary, NC, USA).
First, descriptive analyses of general characteristics,
thrombotic/thromboembolic, and major bleeding events
as well as concomitant medication/procedures and
therapies were performed for characterization of the
MPN cohort. Chi-square test, Fisher’ exact test, and
Wilcoxon-Mann-Whitney test were used to describe the
distribution of categorical and continuous variables be-
tween the different subtypes. Contingency tables were
used to identify the odds of potential risk factors for
thrombotic/thromboembolic and major bleeding events.
A logistic regression model was generated for the pre-
diction of bleeding and vascular events in MPN. In this
analysis, a stepwise selection of defined variables was
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performed with a significance of level of p = 0.10 to enter
and a p value of 0.05 to remain in the model.
All statistical tests were two-sided, and p < 0.05 was
used as the level of significance.
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